A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease

基于肽的即时垂直流检测用于快速诊断莱姆病

基本信息

批准号：
10080510
负责人：
Paul Michael Arnaboldi
金额：
$ 30万
依托单位：
BIOPEPTIDES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-24 至 2021-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10080510
关键词：
Address Antibiotics Antibodies Antigen Targeting Antigens Bacterial Proteins Bedside Testings Binding Binding Proteins Biological Assay Borrelia burgdorferi Borrelia miyamotoi Cells Cellular Phone Centers for Disease Control and Prevention (U.S.)Clinical Clinical Treatment Coupled DBL Oncoprotein Data Defect Detection Development Diagnosis Diagnostic Disease Disease Progression Early Diagnosis Early treatment Epitopes Family Generations Goals ITGB3 gene ImProv Immunoglobulin G Immunoglobulin M Individual Infection Intervention Laboratories Laboratory Diagnosis Legal patent Lyme Disease Machine Learning Maps Measures Membrane Methods Microbe Musculoskeletal System Nature Nervous system structure OspC protein Paper Patient-Focused Outcomes Patients Peptides Phase Physicians Proteins Reader Reporting Research Sampling Serologic tests Serological Signal Transduction Small Business Innovation Research Grant Specificity Speed Spottings System Technology Testing Time Work base biological systems blind clinical Diagnosis cost cost effective cross reactivity decorin binding protein B design diagnostic assay efficacy testing improved innovation member multiplex detection novel strategies point of care point-of-care diagnostics portability preservation prevent prototype rapid diagnosis relapsing fever borrelia screening

项目摘要

Project Summary There is an obvious need for new approaches and better assays for the laboratory diagnosis of Lyme disease. All attempts to develop a practical assay for the direct detection of Borrelia burgdorferi in infected patients have failed. Thus far, all proposed alternatives to serology have been unsuccessful, not cost-effective, or are still in early development. Improving serological detection in early disease is the fastest and most effective way to improve patient outcomes in Lyme disease. The antigen targets utilized in current serodiagnostic assays have considerable defects. They often contain conserved epitopes that cross-react with antibodies raised to other antigens, reducing specificity and requiring the use of a two-tier seroassay paradigm that preserves specificity at the cost of poor sensitivity in the detection of early disease. The use of peptides as serodiagnostic targets demonstrate improved efficacy, but the use of one or two peptides containing single epitopes still provides re- duced sensitivity in early disease. Putting the same old antigen targets into new platforms, no matter how in- novative the platform, will not succeed in improving serodiagnostics for Lyme disease. Both the target anti- gens and assays need an innovative approach. By incorporating unique peptides containing linear epitopes highly specific to B. burgdorferi, into a cutting-edge, multiplex, portable paper-based point-of-care diagnostic assay that uses a cost-effective smartphone-based reader, we aim to transform the diagnosis of Lyme disease. An ideal test for Lyme disease could be performed in a single step and yield an answer on the spot to support diagnosis and direct the course of clinical treatment. We have developed an innovative vertical-flow assay which allows for the multiplexed detection of IgM and IgG binding of up to 25 independent antigen targets in a point-of-care setting. The VFA design allows for uniform flow of sample across the target membrane, creating uniform binding conditions and maximizing developed signal. We coupled this design with a cost-effective portable smart-phone based reader allowing for quantitative measure of antibody binding, eliminating subjectiv- ity. By multiplexing peptide antigens each containing 1-2 epitopes unique to B. burgdorferi from multiple differ- ent antigens expressed at different stages during mammalian infection we can generate a single tier, POC as- say that can specifically and sensitively detect patient antibody at all stages of the disease. The assay can be completed in less than 25 min allowing for rapid in office results to support clinical diagnosis, thereby improving patient outcomes.

项目概要莱姆病的实验室诊断显然需要新的方法和更好的检测方法。所有尝试开发一种实用的检测方法来直接检测感染患者中的伯氏疏螺旋体失败的。迄今为止，所有提出的血清学替代方案均不成功，不具有成本效益，或者仍在研究中。早期发展。改善早期疾病的血清学检测是最快、最有效的方法改善莱姆病患者的治疗效果。当前血清诊断测定中使用的抗原靶点已相当大的缺陷。它们通常含有保守表位，可与其他抗体产生交叉反应抗原，降低特异性并需要使用保留特异性的两层血清测定范例以早期疾病检测的敏感性较差为代价。使用肽作为血清诊断靶标证明了功效的改善，但使用一种或两种含有单一表位的肽仍然可以提供重新疾病早期的敏感性降低。将相同的旧抗原靶点放入新平台，无论如何 - 该平台的创新性不会成功改善莱姆病的血清诊断。两者的目标抗基因和检测需要创新的方法。通过整合含有线性表位的独特肽对伯氏疏螺旋体具有高度特异性，成为尖端、多重、便携式纸质护理点诊断使用经济高效的基于智能手机的读取器进行检测，我们的目标是改变莱姆病的诊断。莱姆病的理想测试可以一步完成，并当场给出答案以支持诊断并指导临床治疗过程。我们开发了一种创新的垂直流测定法允许对多达 25 个独立抗原靶标的 IgM 和 IgG 结合进行多重检测护理点设置。 VFA 设计允许样品均匀地流过目标膜，从而产生统一的结合条件和最大化开发的信号。我们将这种设计与具有成本效益的基于便携式智能手机的阅读器允许定量测量抗体结合，消除主观性。通过多重肽抗原，每个肽抗原含有来自多个不同伯氏疏螺旋体的 1-2 个独特表位，根据哺乳动物感染过程中不同阶段表达的 ent 抗原，我们可以生成单层 POC：据说可以特异性、灵敏地检测疾病各个阶段的患者抗体。该测定可以是不到 25 分钟即可完成，可在办公室快速获得结果以支持临床诊断，从而改善患者的结果。